Anavex Life Sciences Corp.
AVXL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $787 | $730 | $911 | $477 |
| - Cash | $101 | $116 | $121 | $132 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $686 | $614 | $790 | $345 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$13 | $1 | -$11 | -$34 |
| % Margin | – | – | – | – |
| Net Income | -$13 | -$11 | -$12 | -$12 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.16 | -0.13 | -0.14 | -0.14 |
| % Growth | -23.1% | 7.1% | 0% | – |
| Operating Cash Flow | -$12 | -$6 | -$12 | -$7 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$12 | -$6 | -$12 | -$7 |